Advertisement
Editorial board| Volume 45, SUPPLEMENT 2, i-ii, November 2022

Editorial Board

    Open AccessDOI:https://doi.org/10.1016/S2666-1683(22)02450-8
    Editorial Board
    Next ArticleIs semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting in the phase II hypo-FLAME 2.0 trial associated with acceptable acute toxicity?
        This paper is only available as a PDF. To read, Please Download here.

        Article info

        Identification

        DOI: https://doi.org/10.1016/S2666-1683(22)02450-8

        Copyright

        © 2022 European Association of Urology. Published by Elsevier B.V. Published by Elsevier Inc.

        User license

        Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
        How you can reuse Information Icon
        Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

        Permitted

        For non-commercial purposes:

        • Read, print & download
        • Redistribute or republish the final article
        • Text & data mine
        • Translate the article (private use only, not for distribution)
        • Reuse portions or extracts from the article in other works

        Not Permitted

        • Sell or re-use for commercial purposes
        • Distribute translations or adaptations of the article

        Elsevier's open access license policy

        ScienceDirect

        Access this article on ScienceDirect
        We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
        Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


        RELX